Trending...
- EFLOW FX Pioneers Tokenized Real Estate for Greater Accessibility and Growth
- Reality TV Star Vanessa Valente Gets Candid About Life After Temptation Island on Sisters Uncensored
- Rochester: Free Financial Wellness Workshops Saturday
PLYMOUTH MEETING, Pa., Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m. ET on October 1 in New York City. Members of Harmony's senior leadership team along with therapeutic area key opinion leaders will present to investors and research analysts the following:
New data on pitolisant in idiopathic hypersomnia (IH)
Update on pitolisant-HD development program
New data on BP1.15205, a potential best in class orexin-2 agonist
The Harmony Investor Day presentation will be made available following the conclusion of the event on the Investors page of the Harmony Biosciences website. Investors interested in attending the event should contact Brennan Doyle at Harmony Investor Relations at [email protected] or register here to attend in person or participate virtually. Space is limited.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
More on Nyenta.com
Forward Looking Statement:
This presentation includes forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," "may," "could," "might," "continue," "potential," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on current expectations or objectives that are inherently uncertain. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expressed or implied forwarding-looking statements, including, but not limited to the risk factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the SEC. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.
More on Nyenta.com
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
[email protected]
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]
SOURCE Harmony Biosciences
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
- Highlights of the company's late-stage pipeline with key program updates, including:
New data on pitolisant in idiopathic hypersomnia (IH)
Update on pitolisant-HD development program
New data on BP1.15205, a potential best in class orexin-2 agonist
- Scientific rationale for therapeutic efficacy based on mechanisms of action for ZYN002 and EPX100, both in registrational Phase 3 trials
- Market potential for late-stage pipeline assets following recent acquisitions; portfolio now includes three orphan/rare CNS franchises, each with potential peak sales opportunities of $1B - $2B
The Harmony Investor Day presentation will be made available following the conclusion of the event on the Investors page of the Harmony Biosciences website. Investors interested in attending the event should contact Brennan Doyle at Harmony Investor Relations at [email protected] or register here to attend in person or participate virtually. Space is limited.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
More on Nyenta.com
- SJ Auctioneers' online-only auction, October 27, has items ranging from estate silverware to vintage Japanese tin toy buses
- The Power of Now in Baseball - Free for Athletes, Coaches, and Parents
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Looming Votes of CBZ, GVP and AFBI
Forward Looking Statement:
This presentation includes forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," "may," "could," "might," "continue," "potential," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on current expectations or objectives that are inherently uncertain. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expressed or implied forwarding-looking statements, including, but not limited to the risk factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the SEC. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.
More on Nyenta.com
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
- New Rochelle: Main Street Overnight Paving Begins October 9
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
- InventHelp Inventor Develops New Repair Accessory for Footed Pajamas (LJD-401)
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
[email protected]
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]
SOURCE Harmony Biosciences
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Filed Under: Business
0 Comments
Latest on Nyenta.com
- The City Tutors Welcomes Brad Timmers as New Chief Technology Officer to Drive Tech Innovation
- Farther Secures $72 Million Series C from CapitalG and Viewpoint Ventures to Continue Revolutionizing Wealth Management
- Bug Busters Celebrates 40 Years in the Pest Control Industry
- Invenio IT Partners with Vonahi Security to Offer Automated Network Penetration Testing for Enhanced Security
- Rochester: Final International Plaza Market Sunday to Feature Hispanic Heritage Month Celebration
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs
- After 300 miles of New York City driving, AMCI Testing's latest evaluation of Tesla FSD ( Supervised) demonstrates it is clearly not capable of self-driven taxi duty
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGR
- EFLOW FX Pioneers Tokenized Real Estate for Greater Accessibility and Growth
- Rochester: Statement by Mayor Malik D. Evans Regarding Walgreens Store Closures
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
- Rochester Central Library makes local history: First public library to send youth to nation's capital
- Rochester: Final Community Garage Sale and Super Flea of 2024 Sunday at Public Market
- New Rochelle: NR Youth Bureau -Healthy Bites Program
- Reality TV Star Vanessa Valente Gets Candid About Life After Temptation Island on Sisters Uncensored
- NEMTAC Announces Public Comment Period for the NEMTAC 3001-202X Transportation Specialist Education Draft Standard
- What is the Power of We Hosts Together Moving Summit to Combat Gender-Based Violence
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4